Small-molecule APIs: Production
How China, India and Europe split the world's API supply
How China, India and Europe split the world's API supply What this tab covers Who makes it and how much: world capacity and output, utilisation, the top producing countries and companies globally and in India, concentration, new capacity coming, and each region's position.| Measure | Figure | Detail | Source |
|---|---|---|---|
| World capacity | not published globally; capacity is measured in reactor volume (kL) per company | Laurus Labs FY26 | |
| World output | not published globally | ||
| Capacity utilisation | not published | Indian PLI plants are ramping slowly; Chinese overcapacity pushed import prices down 40-50% for some APIs after the scheme launched (IndraStra, June 2026, citing PIB data). | IndraStra (June 2026) |
| Concentration | facility count understates China: by volume of KSMs and intermediates China is far larger; no public top-5 company share | Facility shares are for the US supply chain only and say nothing about tonnes. | US FDA (2019); ORF (Dec 2025) |
| New capacity | PLI bulk drugs: 48 projects approved, 38 commissioned by Dec 2025, about 56,800 t/yr capacity | Lyfius penicillin G 15,000 t/yr (Kakinada, 2024), Kinvan clavulanic acid 400 t/yr, Meghmani para-aminophenol 13,500 t/yr, Centrient atorvastatin 206 t/yr, Andhra Organics sulfadiazine and sartans. Three bulk drug parks (Andhra Pradesh, Gujarat, Himachal Pradesh) under development. | IndraStra citing PIB (June 2026); PSU Watch (2026); Business Today (July 2025) |
Top producing countries
China 13% · 13% of API facilities supplying the US (2019); dominant in KSMs, fermentation and many commodity APIs India 18% · 18% of API facilities supplying the US (2019); third-largest medicine maker by volume European Union 26% · 26% of API facilities supplying the US (2019); Italy, Spain, Ireland, Switzerland strong in complex APIs United States 28% · 28% of API facilities supplying the US (2019); mostly innovator and controlled substances US FDA testimony (Woodcock, Oct 2019); US FDA (2019); Department of Pharmaceuticals Annual Report 2024-25; US FDA (2019)Largest producers: global
| Company | Country | Volume | Year | Source |
|---|---|---|---|---|
| Zhejiang Huahai Pharmaceutical large sartan API supplier; 2018 valsartan NDMA recall | China | not published | 2025 | not published |
| Teva API (TAPI) one of the largest merchant API sellers | Israel | not published | 2025 | not published |
| Lonza (Small Molecules) 41.8% CORE EBITDA margin | Switzerland | 1.611 CHF billion sales | 2025 | Lonza Full-Year Results 2025 |
| WuXi AppTec on US DoD 1260H list from June 2026; preliminary injunction Aug 2026 | China | 45.45 RMB billion revenue (all services) | 2025 | GEN Top 10 CDMOs 2026 |
| Siegfried | Switzerland | 1.328 CHF billion revenue | 2025 | GEN Top 10 CDMOs 2026 |
Largest producers: India
| Company | Country | Volume | Year | Source |
|---|---|---|---|---|
| Divi's Laboratories EBITDA margin 32.6% | India | 106 Rs billion revenue (generics plus custom synthesis) | FY26 | BoB Capital Markets Q4 FY26 review |
| Laurus Labs ARV leader | India | 27.46 Rs billion API sales (generics) | FY26 | Laurus Labs FY26 press release |
| Aurobindo Pharma (Lyfius, Apitoria) largest beta-lactam integrator | India | 15,000 t/yr penicillin G capacity | 2024 | Aurobindo press release |
| Dr Reddy's (API business) large merchant API and CPS unit | India | not published | FY26 | not published here |
| Granules India claims about 30% of global paracetamol | India | not published | 2023 | Angel One (2023) |
India makes most finished generics but imports most KSMs and fermentation intermediates. Import share of APIs by value rose from 68% in FY20 to about 72% in FY24 (estimates cited in Lok Sabha reply coverage, July 2025).
Position by region
| Region | Position |
|---|---|
| US | Generic API supply relies on India and China; BIOSECURE Act (Dec 2025) targets Chinese biotech service firms, and a Section 232 probe on pharma imports opened in 2025. |
| EU | Critical Medicines Act proposed 2025 to rebuild API supply; strong in complex APIs. |
| India | Formulation strength, KSM weakness; PLI and minimum import prices since 2026 to protect new plants. |
| China | Largest KSM and fermentation base; price cuts of 40-50% on some APIs after India's PLI (IndraStra 2026). |
| Japan | Imports many APIs; government funding domestic antibiotic API capacity (indicative). |
| Middle East | Minor producer; 2026 Middle East crisis raised Indian raw material costs (BoB on Divi's, May 2026). |